{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T06:21:59Z","timestamp":1759990919684,"version":"3.37.3"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T00:00:00Z","timestamp":1621814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T00:00:00Z","timestamp":1621814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70112382","70112382"],"award-info":[{"award-number":["70112382","70112382"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Med"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:sec>\n                <jats:title>Abstract<\/jats:title>\n                <jats:p>Arming of oncolytic viruses with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been shown as a viable approach to increase the antitumor efficacy in melanoma. However, melanoma cells may be partially or completely resistant to TRAIL or develop TRAIL resistance, thus counteracting the antitumor efficiency of TRAIL-armed oncolytic viruses. Recently, we found that TRAIL resistance in melanoma cells can be overcome by inhibition of antiapoptotic Bcl-2 protein myeloid cell leukemia 1 (Mcl-1). Here, we investigated whether the cytotoxicity of AdV-TRAIL, an oncolytic adenovirus, which expresses TRAIL after induction by doxycycline (Dox), can be improved in melanoma cells by silencing of Mcl-1. Two melanoma cell lines, the TRAIL-resistant MeWo and the TRAIL-sensitive Mel-HO were investigated. Treatment of both cell lines with AdV-TRAIL resulted in a decrease of cell viability, which was caused by an increase of apoptosis and necrosis. The proapoptotic effects were dependent on induction of TRAIL by Dox and were more pronounced in Mel-HO than in MeWo cells. SiRNA-mediated silencing of Mcl-1 resulted in a further significant decrease of cell viability and a further increase of apoptosis and necrosis in AdV-TRAIL-infected MeWo and Mel-HO cells. However, while in absolute terms, the effects were more pronounced in Mel-HO cells, in relative terms, they were stronger in MeWo cells. These results show that silencing of Mcl-1 represents a suitable approach to increase the cytotoxicity of a TRAIL-armed oncolytic adenovirus in melanoma cells.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Key messages<\/jats:title>\n                <jats:p>\u2022 Cytotoxicity of TRAIL-expressing adenovirus can be enhanced by silencing of Mcl-1.<\/jats:p>\n                <jats:p>\u2022 The effect occurs in TRAIL-sensitive and TRAIL-resistant melanoma cells.<\/jats:p>\n                <jats:p>\u2022 Increase of apoptosis is the main mechanism induced by Mcl-1 silencing.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00109-021-02081-3","type":"journal-article","created":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T06:02:27Z","timestamp":1621836147000},"page":"1279-1291","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Silencing of Mcl-1 overcomes resistance of melanoma cells against TRAIL-armed oncolytic adenovirus by enhancement of apoptosis"],"prefix":"10.1007","volume":"99","author":[{"given":"Beatrice","family":"Tolksdorf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sina","family":"Zarif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Eberle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmet","family":"Hazini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Babette","family":"Dieringer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franziska","family":"J\u00f6nsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Kreppel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Kurreck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7082-4350","authenticated-orcid":false,"given":"Henry","family":"Fechner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,24]]},"reference":[{"key":"2081_CR1","unstructured":"Stewart BW, Wild C (2014) World cancer report 2014. International Agency for Research on Cancer, Lyon, France"},{"key":"2081_CR2","unstructured":"Sundararajan S, Thida AM, Badri T (2021) StatPearls. Metastatic melanoma, Treasure Island (FL)"},{"key":"2081_CR3","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s40257-021-00593-9","volume":"22","author":"DC Ziogas","year":"2021","unstructured":"Ziogas DC, Konstantinou F, Bouros S, Theochari M, Gogas H (2021) Combining BRAF\/MEK inhibitors with immunotherapy in the treatment of metastatic melanoma. Am J Clin Dermatol 22:301\u2013314","journal-title":"Am J Clin Dermatol"},{"key":"2081_CR4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.hoc.2020.08.013","volume":"35","author":"EI Buchbinder","year":"2021","unstructured":"Buchbinder EI (2021) Immune checkpoint therapies for melanoma. Hematol Oncol Clin North Am 35:99\u2013109","journal-title":"Hematol Oncol Clin North Am"},{"key":"2081_CR5","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1093\/intimm\/dxz012","volume":"31","author":"KG Paulson","year":"2019","unstructured":"Paulson KG, Lahman MC, Chapuis AG, Brownell I (2019) Immunotherapy for skin cancer. Int Immunol 31:465\u2013475","journal-title":"Int Immunol"},{"key":"2081_CR6","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1046\/j.0022-202x.2001.01409.x","volume":"117","author":"M Raisova","year":"2001","unstructured":"Raisova M, Hossini AM, Eberle J, Riebeling C, Wieder T, Sturm I, Daniel PT, Orfanos CE, Geilen CC (2001) The Bax\/Bcl-2 ratio determines the susceptibility of human melanoma cells to CD95\/Fas-mediated apoptosis. J Invest Dermatol 117:333\u2013340","journal-title":"J Invest Dermatol"},{"key":"2081_CR7","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1111\/j.0022-202X.2005.23900.x","volume":"125","author":"BM Kurbanov","year":"2005","unstructured":"Kurbanov BM, Geilen CC, Fecker LF, Orfanos CE, Eberle J (2005) Efficient TRAIL-R1\/DR4-mediated apoptosis in melanoma cells by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Invest Dermatol 125:1010\u20131019","journal-title":"J Invest Dermatol"},{"key":"2081_CR8","doi-asserted-by":"publisher","first-page":"656","DOI":"10.3390\/cancers11050656","volume":"11","author":"J Eberle","year":"2019","unstructured":"Eberle J (2019) Countering TRAIL resistance in melanoma. Cancers 11:656","journal-title":"Cancers"},{"key":"2081_CR9","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S1074-7613(00)80212-5","volume":"12","author":"FC Kischkel","year":"2000","unstructured":"Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A (2000) Apo2L\/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 12:611\u2013620","journal-title":"Immunity"},{"key":"2081_CR10","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/sj.cdd.4401160","volume":"10","author":"U Fischer","year":"2003","unstructured":"Fischer U, J\u00e4nicke RU, Schulze-Osthoff K (2003) Many cuts to ruin: a comprehensive update of caspase substrates. Cell Death Differ 10:76\u2013100","journal-title":"Cell Death Differ"},{"issue":"2","key":"2081_CR11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/nrd3627","volume":"11","author":"S Fulda","year":"2012","unstructured":"Fulda S, Vucic D (2012) Targeting IAP proteins for therapeutic intervention in cancer. Nature reviews. Drug Des Discov 11(2):109\u2013124","journal-title":"Drug Des Discov"},{"key":"2081_CR12","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/5517","volume":"5","author":"H Walczak","year":"1999","unstructured":"Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T et al (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5:157\u2013163","journal-title":"Nat Med"},{"key":"2081_CR13","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.biopha.2017.12.082","volume":"98","author":"A Naimi","year":"2018","unstructured":"Naimi A, Movassaghpour AA, Hagh MF, Talebi M, Entezari A, Jadidi-Niaragh F, Solali S (2018) TNF-related apoptosis-inducing ligand (TRAIL) as the potential therapeutic target in hematological malignancies. Biomed Pharmacother 98:566\u2013576","journal-title":"Biomed Pharmacother"},{"key":"2081_CR14","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1158\/0008-5472.CAN-08-1160","volume":"69","author":"R Edukulla","year":"2009","unstructured":"Edukulla R, Woller N, Mundt B, Knocke S, Gurlevik E, Saborowski M, Malek N, Manns MP, Wirth T, Kuhnel F et al (2009) Antitumoral immune response by recruitment and expansion of dendritic cells in tumors infected with telomerase-dependent oncolytic viruses. Cancer Res 69:1448\u20131458","journal-title":"Cancer Res"},{"key":"2081_CR15","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nrc.2015.17","volume":"16","author":"ARD Delbridge","year":"2016","unstructured":"Delbridge ARD, Grabow S, Strasser A, Vaux DL (2016) Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies. Nat Rev Cancer 16:99\u2013109","journal-title":"Nat Rev Cancer"},{"key":"2081_CR16","first-page":"49","volume":"15","author":"PE Czabotar","year":"2014","unstructured":"Czabotar PE, Lessene G, Strasser A, Adams JM (2014) Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nature reviews. Mo Cell Biol 15:49\u201363","journal-title":"Mo Cell Biol"},{"key":"2081_CR17","doi-asserted-by":"publisher","first-page":"8482","DOI":"10.1002\/jcp.26786","volume":"233","author":"A de Blasio","year":"2018","unstructured":"de Blasio A, Vento R, Di Fiore R (2018) Mcl-1 targeting could be an intriguing perspective to cure cancer. J Cell Physiol 233:8482\u20138498","journal-title":"J Cell Physiol"},{"key":"2081_CR18","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/nature08822","volume":"463","author":"R Beroukhim","year":"2010","unstructured":"Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, Mc Henry KT, Pinchback RM, Ligon AH, Cho YJ, Haery L, Greulich H, Reich M, Winckler W, Lawrence MS, Weir BA, Tanaka KE, Chiang DY, Bass AJ, Loo A, Hoffman C, Prensner J, Liefeld T, Gao Q, Yecies D, Signoretti S, Maher E, Kaye FJ, Sasaki H, Tepper JE, Fletcher JA, Tabernero J, Baselga J, Tsao MS, Demichelis F, Rubin MA, Janne PA, Daly MJ, Nucera C, Levine RL, Ebert BL, Gabriel S, Rustgi AK, Antonescu CR, Ladanyi M, Letai A, Garraway LA, Loda M, Beer DG, True LD, Okamoto A, Pomeroy SL, Singer S, Golub TR, Lander ES, Getz G, Sellers WR, Meyerson M (2010) The landscape of somatic copy-number alteration across human cancers. Nature 463:899\u2013905","journal-title":"Nature"},{"key":"2081_CR19","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ccr.2006.03.027","volume":"9","author":"M Certo","year":"2006","unstructured":"Certo M, Del Gaizo MV, Nishino M, Wei G, Korsmeyer S, Armstrong SA, Letai A (2006) Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9:351\u2013365","journal-title":"Cancer Cell"},{"key":"2081_CR20","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/mt.2009.266","volume":"18","author":"M Yamamoto","year":"2010","unstructured":"Yamamoto M, Curiel DT (2010) Current issues and future directions of oncolytic adenoviruses. Mol Ther 18:243\u2013250","journal-title":"Mol Ther"},{"key":"2081_CR21","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/cgt.2009.3","volume":"16","author":"JJ Cody","year":"2009","unstructured":"Cody JJ, Douglas JT (2009) Armed replicating adenoviruses for cancer virotherapy. Cancer Gene Ther 16:473\u2013488","journal-title":"Cancer Gene Ther"},{"key":"2081_CR22","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1111\/jcmm.12397","volume":"19","author":"Y Yang","year":"2015","unstructured":"Yang Y, Xu H, Huang W, Ding M, Xiao J, Yang D, Li H, Liu X-Y, Chu L (2015) Targeting lung cancer stem-like cells with TRAIL gene armed oncolytic adenovirus. J Cell Mol Med 19:915\u2013923","journal-title":"J Cell Mol Med"},{"key":"2081_CR23","doi-asserted-by":"publisher","first-page":"5224","DOI":"10.1158\/1078-0432.CCR-06-0244","volume":"12","author":"F Dong","year":"2006","unstructured":"Dong F, Wang L, Davis JJ, Hu W, Zhang L, Guo W, Teraishi F, Ji L, Fang B (2006) Eliminating established tumor in nu\/nu nude mice by a tumor necrosis factor-alpha-related apoptosis-inducing ligand-armed oncolytic adenovirus. Clin Cancer Res 12:5224\u20135230","journal-title":"Clin Cancer Res"},{"key":"2081_CR24","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1089\/hum.2010.108","volume":"22","author":"LF Fecker","year":"2011","unstructured":"Fecker LF, Ruckert S, Kurbanov BM, Schmude M, Stockfleth E, Fechner H, Eberle J (2011) Efficient melanoma cell killing and reduced melanoma growth in mice by a selective replicating adenovirus armed with tumor necrosis factor-related apoptosis-inducing ligand. Hum Gene Ther 22:405\u2013417","journal-title":"Hum Gene Ther"},{"key":"2081_CR25","doi-asserted-by":"publisher","first-page":"9131","DOI":"10.1038\/sj.onc.1207228","volume":"22","author":"J Eberle","year":"2003","unstructured":"Eberle J, Fecker LF, Hossini AM, Wieder T, Daniel PT, Orfanos CE, Geilen CC (2003) CD95\/Fas signaling in human melanoma cells. conditional expression of CD95L\/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xenotransplants. Oncogene 22:9131\u20139141","journal-title":"Oncogene"},{"key":"2081_CR26","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/j.1600-0749.1995.tb00679.x","volume":"8","author":"J Eberle","year":"1995","unstructured":"Eberle J, Garbe C, Wang N, Orfanos CE (1995) Incomplete expression of the tyrosinase gene family (tyrosinase, TRP-1, and TRP-2) in human malignant melanoma cells in vitro. Pigment Cell Res 8:307\u2013313","journal-title":"Pigment Cell Res"},{"key":"2081_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030821","volume":"7","author":"D Senft","year":"2012","unstructured":"Senft D, Berking C, Graf SA, Kammerbauer C, Ruzicka T, Besch R (2012) Selective induction of cell death in melanoma cell lines through targeting of Mcl-1 and A1. PLoS One 7:e30821. https:\/\/doi.org\/10.1371\/journal.pone.0030821","journal-title":"PLoS One"},{"key":"2081_CR28","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.antiviral.2010.08.002","volume":"88","author":"A Eckstein","year":"2010","unstructured":"Eckstein A, Grossl T, Geisler A, Wang X, Pinkert S, Pozzuto T, Schwer C, Kurreck J, Weger S, Vetter R et al (2010) Inhibition of adenovirus infections by siRNA-mediated silencing of early and late adenoviral gene functions. Antivir Res 88:86\u201394","journal-title":"Antivir Res"},{"key":"2081_CR29","first-page":"4663","volume":"62","author":"DM Nettelbeck","year":"2002","unstructured":"Nettelbeck DM, Rivera AA, Balague C, Alemany R, Curiel DT (2002) Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer\/promoter. Cancer Res 62:4663\u20134670","journal-title":"Cancer Res"},{"key":"2081_CR30","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.omtn.2017.07.002","volume":"8","author":"K Schaar","year":"2017","unstructured":"Schaar K, Geisler A, Kraus M, Pinkert S, Pryshliak M, Spencer JF, Tollefson AE, Ying B, Kurreck J, Wold WS, Klopfleisch R, Toth K, Fechner H (2017) Anti-adenoviral artificial microRNAs expressed from AAV9 vectors inhibit human adenovirus infection in immunosuppressed Syrian hamsters. Mol Ther Nucleic Acids 8:300\u2013316","journal-title":"Mol Ther Nucleic Acids"},{"key":"2081_CR31","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1038\/nprot.2006.238","volume":"1","author":"C Riccardi","year":"2006","unstructured":"Riccardi C, Nicoletti I (2006) Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc 1:1458\u20131461","journal-title":"Nat Protoc"},{"key":"2081_CR32","doi-asserted-by":"publisher","first-page":"3364","DOI":"10.1038\/sj.onc.1210134","volume":"26","author":"BM Kurbanov","year":"2007","unstructured":"Kurbanov BM, Fecker LF, Geilen CC, Sterry W, Eberle J (2007) Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappaB but is related to downregulation of initiator caspases and DR4. Oncogene 26:3364\u20133377","journal-title":"Oncogene"},{"key":"2081_CR33","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1001\/archopht.123.5.654","volume":"123","author":"H Li","year":"2005","unstructured":"Li H, Niederkorn JY, Neelam S, Alizadeh H (2005) Resistance and susceptibility of human uveal melanoma cells to TRAIL-induced apoptosis. Arch Ophthalmol 123:654\u2013661","journal-title":"Arch Ophthalmol"},{"key":"2081_CR34","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1002\/mc.23253","volume":"59","author":"Z Sarif","year":"2020","unstructured":"Sarif Z, Tolksdorf B, Fechner H, Eberle J (2020) Mcl-1 targeting strategies unlock the proapoptotic potential of TRAIL in melanoma cells. Mol Carcinog 59:1256\u20131268","journal-title":"Mol Carcinog"},{"key":"2081_CR35","doi-asserted-by":"publisher","first-page":"40667","DOI":"10.18632\/oncotarget.5842","volume":"6","author":"Y Qin","year":"2015","unstructured":"Qin Y, Zhang Q, Lee S, WI Z, Liu YR, Liu HJ, Zhao D, Chen S, Xiao T, Meng J et al (2015) Doxycycline reverses epithelial-to-mesenchymal transition and suppresses the proliferation and metastasis of lung cancer cells. Oncotarget 6:40667\u201340679","journal-title":"Oncotarget"},{"key":"2081_CR36","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3322\/caac.21409","volume":"67","author":"JE Gershenwald","year":"2017","unstructured":"Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM, McArthur GA et al (2017) Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 67:472\u2013492","journal-title":"CA Cancer J Clin"},{"key":"2081_CR37","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ejcb.2013.11.003","volume":"93","author":"SA Quast","year":"2013","unstructured":"Quast SA, Berger A, Plotz M, Eberle J (2013) Sensitization of melanoma cells for TRAIL-induced apoptosis by activation of mitochondrial pathways via Bax. Eur J Cell Biol 93:42\u201348","journal-title":"Eur J Cell Biol"},{"key":"2081_CR38","doi-asserted-by":"publisher","first-page":"10491","DOI":"10.1074\/jbc.M412819200","volume":"280","author":"C Weng","year":"2005","unstructured":"Weng C, Li Y, Xu D, Shi Y, Tang H (2005) Specific cleavage of Mcl-1 by caspase-3 in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Jurkat leukemia T cells. J Biol Chem 280:10491\u201310500","journal-title":"J Biol Chem"},{"key":"2081_CR39","doi-asserted-by":"publisher","first-page":"12243","DOI":"10.1128\/JVI.78.22.12243-12251.2004","volume":"78","author":"MAI Abou El Hassan","year":"2004","unstructured":"Abou El Hassan MAI, van der Meulen-Muileman I, Abbas S, Kruyt FAE (2004) Conditionally replicating adenoviruses kill tumor cells via a basic apoptotic machinery-independent mechanism that resembles necrosis-like programmed cell death. J Virol 78:12243\u201312251","journal-title":"J Virol"},{"key":"2081_CR40","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/1471-2407-14-74","volume":"14","author":"S Voigt","year":"2014","unstructured":"Voigt S, Philipp S, Davarnia P, Winoto-Morbach S, R\u00f6der C, Arenz C, Trauzold A, Kabelitz D, Sch\u00fctze S, Kalthoff H, Adam D (2014) TRAIL-induced programmed necrosis as a novel approach to eliminate tumor cells. BMC Cancer 14:74","journal-title":"BMC Cancer"},{"key":"2081_CR41","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/j.bbabio.2006.06.014","volume":"1757","author":"N Festjens","year":"2006","unstructured":"Festjens N, Vanden Berghe T, Vandenabeele P (2006) Necrosis, a well-orchestrated form of cell demise: signalling cascades, important mediators and concomitant immune response. Biochim Biophys Acta 1757:1371\u20131387","journal-title":"Biochim Biophys Acta"},{"key":"2081_CR42","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1126\/science.1172308","volume":"325","author":"D-W Zhang","year":"2009","unstructured":"Zhang D-W, Shao J, Lin J, Zhang N, Lu B-J, Lin S-C, Dong M-Q, Han J (2009) RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science 325:332\u2013336","journal-title":"Science"},{"key":"2081_CR43","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.immuni.2013.02.003","volume":"38","author":"A Kaczmarek","year":"2013","unstructured":"Kaczmarek A, Vandenabeele P, Krysko DV (2013) Necroptosis: the release of damage-associated molecular patterns and its physiological relevance. Immunity 38:209\u2013223","journal-title":"Immunity"},{"key":"2081_CR44","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nature19830","volume":"538","author":"A Kotschy","year":"2016","unstructured":"Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno AL, Le Toumelin-Braizat G, Chanrion M, Kelly GL, Gong J-N, Moujalled DM et al (2016) The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature 538:477\u2013482","journal-title":"Nature"},{"key":"2081_CR45","doi-asserted-by":"publisher","first-page":"5341","DOI":"10.1038\/s41467-018-07551-w","volume":"9","author":"AE Tron","year":"2018","unstructured":"Tron AE, Belmonte MA, Adam A, Aquila BM, Boise LH, Chiarparin E, Cidado J, Embrey KJ, Gangl E, Gibbons FD, Gregory GP, Hargreaves D, Hendricks JA, Johannes JW, Johnstone RW, Kazmirski SL, Kettle JG, Lamb ML, Matulis SM, Nooka AK, Packer MJ, Peng B, Rawlins PB, Robbins DW, Schuller AG, Su N, Yang W, Ye Q, Zheng X, Secrist JP, Clark EA, Wilson DM, Fawell SE, Hird AW (2018) Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nature Comm 9:5341","journal-title":"Nature Comm"},{"key":"2081_CR46","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1126\/science.1106114","volume":"307","author":"JT Opferman","year":"2005","unstructured":"Opferman JT, Iwasaki H, Ong CC, Suh H, S-i M, Akashi K, Korsmeyer SJ (2005) Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science 307:1101\u20131104","journal-title":"Science"},{"key":"2081_CR47","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nature02067","volume":"426","author":"JT Opferman","year":"2003","unstructured":"Opferman JT, Letai A, Beard C, Sorcinelli MD, Ong CC, Korsmeyer SJ (2003) Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 426:671\u2013676","journal-title":"Nature"},{"key":"2081_CR48","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1101\/gad.215871.113","volume":"27","author":"RL Thomas","year":"2013","unstructured":"Thomas RL, Roberts DJ, Kubli DA, Lee Y, Quinsay MN, Owens JB, Fischer KM, Sussman MA, Miyamoto S, Gustafsson \u00c5B (2013) Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure. Genes Dev 27:1365\u20131377","journal-title":"Genes Dev"}],"container-title":["Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-021-02081-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00109-021-02081-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-021-02081-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T09:05:11Z","timestamp":1629104711000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00109-021-02081-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,24]]},"references-count":48,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["2081"],"URL":"https:\/\/doi.org\/10.1007\/s00109-021-02081-3","relation":{},"ISSN":["0946-2716","1432-1440"],"issn-type":[{"type":"print","value":"0946-2716"},{"type":"electronic","value":"1432-1440"}],"subject":[],"published":{"date-parts":[[2021,5,24]]},"assertion":[{"value":"26 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Involvement of human participants"}},{"value":"Not applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal experiments"}}]}}